WSJ: Dense breast notifications raise confusing issues for women

The Wall Street Journal poses an interesting question for both the specialty of radiology and the millions of women in 21 states who will be notified that they have dense breasts: What should they do about it?

While it recognizes the emergence of new technologies that promise better detection of cancers, the “New Screening Tests for Hard-to-Spot Breast Cancers” raises a number of issues for women receiving such a notice. They include an increased probability of false positives and the fact that most alternatives to mammography are more expensive.

“It’s a very confusing time,” Emily Conant, MD, chief of breast imaging, University of Pennsylvania Medical Center, told the WSJ. “This legislation has happened before we have a medical consensus about what to tell women.”

While Conant said that all women who are imaged at the University of Pennsylvania Medical Center  women’s center receive breast tomosynthesis, the JAMA study in which she participated did not look specifically at women with dense breasts.

The article also cites contradictory thinking  on breast ultrasound, the expense of breast MRI and the increased radiation dose associated with molecular breast imaging.

“Doctors say that a large, randomized clinical trial comparing all the options for women with dense breasts would be helpful,” the author writes. “Meanwhile, they can help women understand the pros and cons for themselves whether to seek additional tests.”

Cheryl Proval,

Vice President, Executive Editor, Radiology Business

Cheryl began her career in journalism when Wite-Out was a relatively new technology. During the past 16 years, she has covered radiology and followed developments in healthcare policy. She holds a BA in History from the University of Delaware and likes nothing better than a good story, well told.

Around the web

The nuclear imaging isotope shortage of molybdenum-99 may be over now that the sidelined reactor is restarting. ASNC's president says PET and new SPECT technologies helped cardiac imaging labs better weather the storm.

CMS has more than doubled the CCTA payment rate from $175 to $357.13. The move, expected to have a significant impact on the utilization of cardiac CT, received immediate praise from imaging specialists.

The all-in-one Omni Legend PET/CT scanner is now being manufactured in a new production facility in Waukesha, Wisconsin.